TYK2 Inhibitors for the Treatment of Psoriasis | Ronald Vender, MD, FRCPC | Canada

New Understandings of Disease Relapse and Progression | Irène Gallais Sérézal, MD, PhD | France

Drs. Armstrong & Gordon discuss the latest psoriasis updates from #AAD2021 https://bit.ly/3mr1ftO

Target Product Profile (TPP) Development Overview & Best Practices

Guidewire Fundamentals, with Dr. Dragos Alexandru

Stress Nuclear: Methodology and Case Studies (Faisal Nabi, MD) January 28, 2020

JAK/TYK2 Topic Panel

JAK inhibitors in Psoriasis and PsA

«Мозговой срыв с доктором Кларком». Эпизод 2: Инсульт

Innovations in Systemic Treatments for Psoriasis | Andrew Blauvelt, MD, MBA | United States

The Natural History of Psoriasis: Insights into Clinical & Genetic Markers | Axel Svedbom, MSc, PhD

Advancing Care in Heart Failure: Strategies for Managing Acute Decompensated HF (R. Yousefzai, MD)

Механизм действия ингибиторов JAK

Колоректальный рак и иммунотерапия с доктором Ван Моррисом

IPC at CDA: Insights and Conversations with Psoriasis Experts

Torsten Wiesel (Rockefeller University): Exploring the Visual Brain

New Insights in the Pathogenesis of Psoriasis | Johann Gudjonsson, MD, PhD | United States

DAY 2 | 2025 CIHCC | Dr. David Wolinsky | Cleveland Clinic

Mechanisms of Topical Drug Delivery: Opportunities for Psoriasis?| Robert Rissmann, PhD| Netherlands

P450 Enzyme System (Inducers, Inhibitors, & Subtypes)

Лечение инвазивной дольковой карциномы HR+ — OncBrothers (Рохит и Рахул Госейн) с доктором Джейсо...